Bristol-Myers Squibb Company (NYSE:BMY) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 1:05 PM ET Company Participants Chris Boerner - Chief Executive Officer David Elkins - Executive Vice President and Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Okay, great. Thanks for joining us everybody. I’m Terence Flynn, the U.S. Biopharma Analyst here at Morgan Stanley. Before we get started for important disclosures, please see the Morg ...

Rebounding growth could make shares of this leading drugmaker a big winner.Bristol Myers Squibb (BMY 0.46%) has struggled to manage the loss of exclusivity now that some of its top-selling drugs are facing competition from generics. Disappointing results from the pharmaceutical giant have pressured the stock in recent years; it's currently down about 34% from its record high in 2022.The backdrop is concerning. But the good news is that the company's latest update signaled what could be the start of a long-a ...

No stock is perfect, but quality businesses can stand the test of time in your portfolio.While a full-fledged, prolonged stock market correction could impact shares across a range of industries, investors with capital on hand can find that these periods present fortuitous opportunities to put cash to work. If you have the risk appetite to invest right now, there are plenty of tried-and-true businesses that have stood the test of time and can do so in a long-term investor's portfolio.Large-cap stocks, which ...

Bristol Myers Squibb (BMY) ended the recent trading session at $49.95, demonstrating a +0.46% swing from the preceding day's closing price. This move lagged the S&P 500's daily gain of 1.01%. Elsewhere, the Dow gained 0.55%, while the tech-heavy Nasdaq added 1.13%.Shares of the biopharmaceutical company have appreciated by 3.22% over the course of the past month, underperforming the Medical sector's gain of 4.91% and outperforming the S&P 500's gain of 2.5%.The upcoming earnings release of Bristol Myers Squ ...

Key TakeawaysSeveral pharmaceutical stocks moved higher Wednesday, bucking downward pressure on the broader markets.An array of clinical trial results and regulatory decisions helped boost shares of Gilead Sciences, Bristol-Myers Squibb, and Vertex Pharmaceuticals.The pharma industry has underperformed in 2024 despite several companies making headlines with blockbuster weight-loss treatments. Shares of several drugmakers and biotechnology firms moved higher on Wednesday, notching some of the day's top perfo ...

Unlock steady income and growth potential with these high-yield, low-risk dividend powerhouses.High-yield dividend stocks can be enticing, with several academic studies showing that stocks yielding above 3% tend to outperform most other asset classes when held for 20 years or longer. However, dividend yield isn't the most important metric to consider when evaluating stocks with cash or stock distributions.A recent report by Hartford Funds reveals a crucial insight: Dividend stocks with payout ratios below 7 ...

These underappreciated dividend payers offer yields above 4% at recent prices.The past year has been terrific for most stocks. The S&P 500 index rose 27.5% during the 12 months ended Aug. 26.It's always nice to see the value of your portfolio rise during a bull market, but it also makes it hard to find stocks to buy at reasonable valuations.Investors seeking reliable dividend stocks that still look like bargains will be glad to know that not all of the S&P 500's components have had a great year. Pfizer (PFE ...

Core Viewpoint - Bristol Myers (BMY) has received FDA acceptance for its supplemental Biologics License Application (sBLA) for the immunotherapy drug Opdivo (nivolumab) in combination with Yervoy (ipilimumab) as a potential first-line treatment for adult patients with unresectable hepatocellular carcinoma (HCC) [1] Company Summary - The sBLA is based on the late-stage CheckMate-9DW study, which demonstrated a statistically significant improvement in overall survival for the Opdivo plus Yervoy combination compared to Lenvima or Nexavar [1] - A final decision from the FDA is expected on April 21, 2025 [1] - Opdivo is already indicated in the U.S. for HCC patients previously treated with Nexavar under accelerated approval [2] - Bristol Myers' shares have decreased by 5.6% year-to-date, while the industry has grown by 1.1% [2] Industry Summary - HCC is the most common type of primary liver cancer, accounting for 75-85% of liver cancers, and is often diagnosed at advanced stages with limited treatment options [2] - The European Medicines Agency (EMA) has validated Bristol Myers' type II variation application for the Opdivo/Yervoy combination as a potential first-line treatment for advanced HCC [5] - Competitors in the HCC market include AstraZeneca, which has an approved combination therapy of Imfinzi (durvalumab) and Imjudo (tremelimumab) for first-line treatment of advanced HCC [6]

Bristol Myers Squibb (BMY) announced that the European Medicines Agency (“EMA”) has validated its type II variation application to expand the indication for CD19-directed chimeric antigen receptor (CAR) T cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel).The application seeks to expand Breyanzi’s label to include the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy.Validation of the application confirms th ...

With yields above 4%, these stocks could do a lot to boost your passive income streamThe S&P 500 index is up by about 16% so far this year. Many of the index's dividend payers have raised their payouts, but not nearly as much as their stock prices have risen. As a result, the average dividend-paying stock in the benchmark index offers a paltry 1.3% yield at recent prices.Luckily, there are still a handful of top dividend payers trading for low enough prices to offer high yields. Here's why they could be gre ...